News & Media
Contact
Home
About Us
Our Commitment
The Story Behind Our Name
Leadership
Board of Directors
Our Approach
Precision Medicines
Overcoming Resistance
Novel Biomarkers
Pipeline
Ziftomenib
Tipifarnib
KO-2806
Posters and Presentations
Scientific Manuscripts
Access To Investigational Drugs Outside a Clinical Study
Clinical Trials
Overview of Clinical Trials
Ziftomenib Clinical Trials
KOMET-001 – AML
KOMET-007 – AML
KOMET-008 – AML
Tipifarnib Clinical Trials
KURRENT-HN – HNSCC
KO-2806 Clinical Trials
FIT-001 – Solid Tumors
Patients & Caregivers
Acute Leukemias
Head & Neck Cancer
Investors
Overview
Press Releases
Events & Presentations
Corporate Governance
Financial Information
Analyst Coverage
FAQs
Contact
Careers
Values
Life At Kura
Benefits
Open Positions
News & Media
Contact
Menu
Menu
Preliminary Phase 1/2A Data From the KOMET-001 First in Human Study of the Menin-KMT2A (MLL) Inhibitor KO-539 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Scroll to top
Scroll to top
Scroll to top